Analyst Ratings For GlaxoSmithKline plc (LON:GSK)
Today, Beaufort Securities reiterated its Buy rating on GlaxoSmithKline plc (LON:GSK) with a price target of GBX 1,750.
There are 2 sell ratings, 12 hold ratings, 9 buy ratings on the stock.
The current consensus rating on GlaxoSmithKline plc (LON:GSK) is Hold (Score: 2.30) with a consensus target price of GBX 1,744.55 per share, a potential .
Some recent analyst ratings include
- 2/16/2017-Beaufort Securities Reiterated Rating of Buy.
- 2/14/2017-Liberum Capital Reiterated Rating of Buy.
- 2/13/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 2/10/2017-Shore Capital Reiterated Rating of Hold.
- 2/9/2017-Credit Suisse Group Reiterated Rating of Neutral.
About GlaxoSmithKline plc (LON:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.
Recent Trading Activity for GlaxoSmithKline plc (LON:GSK)
Shares of GlaxoSmithKline plc closed the previous trading session at 1,611.50 up +17.00 1.07% with 6,561,798 shares trading hands.